Sign in
Not yet taking people in GermanyPhase 2

Tests colchicine in people with heart failure and a blood-cell gene change

Tests colchicine in adults with reduced-function heart failure and CHIP gene mutations.

Key facts

Who runs it
Goethe University Frankfurt
Where
Frankfurt Am Main, GermanySee the site
Registry title
Randomized, controlled, double-blind trial to investigate the effect of colchicin on the endothelial function in patients with CHIP mutations and chronic heart failure with reduced left ventricular function (CHIP-HF)
Status
Not yet recruiting
Phase
Phase 2
People taking part
100 people, planned
Started
17 Feb 2022
Planned end
1 Mar 2026
Type of study
Interventional
Record updated
5 November 2024

Who can take part

AI summary

From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.

The trial is looking for adults with long-term heart failure from a damaged heart muscle after reduced blood flow, with a weak pumping heart, and with known CHIP gene changes (DNMT3A and TET2).

Age
18 years or older
Sex
All sexes can join.
Disease stage
Ischemic cardiomyopathy with reduced left ventricular function (LVEF 40% or lower). Stable heart failure, NYHA II-III.
Earlier treatment
Constant optimal evidence-based medical treatment for at least 4 weeks.
Biomarker or test result
Known status of CHIP mutations (DNMT3A and TET2).

Main reasons for not taking part

  • Acute decompensated heart failure (NYHA IV)
  • Known intolerance to Colchicine
  • Heart failure not caused by reduced blood flow to the heart
  • Acute coronary syndrome or invasive procedure within three months before joining
  • Active cancer or active infection

The registry criteria, word for word

Show all 16 criteriaShow less

Who can take part

  • Patients (m/f) age >/=18
  • Ischemic cardiomyopathy with reduced left ventricular function (LVEF </= 40%)
  • Stable heart insufficiency (NYHA II-III) under constant (at least 4 weeks) optimal evidence based medical treatment
  • Known status of CHIP mutations (DNMT3A and TET2)
  • Signed Informed Consent after detailed information
  • Negative pregnancy testing, high effective method of contraception (women of child bearing potential)

Who cannot take part

  • Acute coronary syndromes within three months prior to inclusion
  • Invasive procedure within three months prior to inclusion
  • Acute decompensated heart failure (NYHA IV; HF>110 bpm; systolic blood pressure < 90mmHg
  • Non ischemic etiology of heart failure
  • Active malignancy
  • Ejection fraction > LVEF 40%
  • Active infection (hs-CRP > 10 mg/dl)
  • Liver cirrhosis, CHILD C (ALT < 60 U/l; AST < 60 U/l; Total Bilirubin < 2 mg/dl)
  • Renal insufficiency grade 5 (GFR<15 ml/min/1.73m²)
  • Known intolerance to Colchicine

Where in Germany

  • Goethe University FrankfurtFrankfurt Am Main, GermanyNot yet recruiting

About the trial

What the trial wants to find out

Efficay and safety of Colchicine in patients with HFrEF and clonal hematopoiesis of indeterminate potential - effects on endothelial cell function, inflammatory biomarkers and inflammatory genetic signatures

Questions to ask the study team

  1. How often do I need to come in, and for how long each time?
  2. Are travel costs paid?
  3. Can I keep my own doctor?
  4. What happens if I want to stop?

Contact the study team: see the registry record

Print a page for my doctor

Saves a reminder to your own calendar to look at this page again. Frontlight sends no messages and does not know you set it.

Data and sources

Registry record
Listed on the EU's official list of trials (CTIS).How to verify a trial in the registry
Official title
Randomized, controlled, double-blind trial to investigate the effect of colchicin on the endothelial function in patients with CHIP mutations and chronic heart failure with reduced left ventricular function (CHIP-HF)
Plain-language title
Tests colchicine in people with heart failure and a blood-cell gene changeGenerated from the registry record. The registry title is the official one.
AI summary
From the trial's eligibility criteria. Read by machine on 9 November 2026.
Record updated
5 November 2024